Evidence has accumulated that the initiation of blood clotting may involve the participation of a plasma thromboplastic factor capable of inducing the conversion of prothrombin to thrombin (1) (2) (3) (4) (5) (6) (7) . The activation of this factor does not appear to require the presence of blood platelets (8) , although platelets seem to potentiate its action (8) (9) (10) . Elucidation of the r6le of this plasma factor has largely depended upon the observation of apparent alterations in its activity in pathologic states. Thus, the coagulation defect in hemophilia seems best explained by deficient activity of a plasma thromboplastic factor (11) .
In the experiments to be described, further information has been provided by the study of an anticoagulant with peculiar properties. This anticoagulant was present in the plasma of a patient with an unusual hemorrhagic disorder. The patient's plasma inhibited the coagulation of normal blood. The inhibitory substance was precipitable with a globulin fraction. It did not appear to inhibit thrombin, prothrombin, or accelerator globulin, nor did it inhibit the activity of platelets or of thromboplastin from a variety of sources. However, the anticoagulant did inhibit the clot accelerating effect of glass surfaces on normal platelet-free plasma. The mode of action of this anticoagulant can be explained best by assuming the presence in platelet-free plasma of a thromboplastic mechanism.
CASE REPORT
The patient was a 37 year old housewife whose case history was previously described by Chargaff and West (12) . There was no family history of bleeding, nor did either of her two children display hemorrhagic manifestations. The patient had three spontaneous abortions at ages 21, 23, and 30 years. and she was delivered of normal children at the ages of 23 and 32. Following the third abortion the patient bled profusely and was transfused with 500 cc. of whole blood. Since that time she had had persistent evidence of a hemorrhagic diathesis with vaginal bleeding, cutaneous ecchymoses, deforming hemarthroses, bleeding gums, and hemorrhage following tooth extractions. She had been treated elsewhere without benefit with multiple blood transfusions, antihemophilic globulin, splenic irradiation, protamine sulfate, "Rutarbin," "Koagamin," and ovarian irradiation. On physical examination the findings of note were cutaneous ecchymoses, and limitation of motion and deformity of several of the large joints attributable to old hemarthroses. The remainder of the physical examination was not remarkable. The whole blood clotting time was prolonged to between three and five hours, but the prothrombin time was normal.
METHODS
The term "plasma thromboplastic factor" is employed to designate the substance or substances in plasma which under certain conditions may initiate the conversion of prothrombin to thrombin. The substance responsible for this activity has not been isolated or identified, but is apparently related to the antihemophilic factor. In this report the term "native plasma" refers to plasma obtained without the addition of anticoagulant and freed from formed elements by centrifugation.
Essentially platelet-free plasma was obtained by methods previously described (7, 8 The anticoagulant activity of plasma and plasma fractions prepared from the patient's blood was assayed by determining their clot-retarding effect on normal whole blood (13) .
The patient's native plasma was dialyzed in 1 inch No-jax cellophane sausage casings against barbital buffer at 20 C. The cellophane bag was rotated continually during this procedure by an electric motor. Nine and one-half ml. of plasma were dialyzed against 350 ml. of buffer for 24 hours, the buffer solution being completely changed five times. The patient's plasma remained fluid during and after dialysis.
Protein fractions of the patient's plasma were obtained by precipitation with ammonium sulfate. Essentially platelet-free plasma was citrated. It was then diluted with an ammonium sulfate solution which had been saturated at room temperature and neutralized to pH 7 with concentrated ammonium hydroxide. The fraction precipitated by 25% saturation with ammonium sulfate was separated by centrifugation at room temperature. Successive fractionations of the supernatant fluid were carried out with increasing concentrations of ammonium sulfate. The precipitates obtained were redissolved in buffer and dialyzed for one hour against running tap water and then against frequent changes of buffer for 16 hours. The supernatant fluid remaining after half saturation with ammonium sulfate was also dialyzed in the same manner. When dialysis was completed, the volume of each fraction was measured.
In the original preparation, the fraction containing the most anticoagulant activity was that precipitated between 25% and 33%yo saturated ammonium sulfate. Therefore, this fraction was again prepared in the following manner: Native plasma was oxalated and filtered through a Seitz ST filter in order to decrease the concentration of prothrombin. The filtrate was diluted with an equal volume of water, and ammonium sulfate added to provide a final concentration of 25%o. The precipitate was removed by centrifugation and discarded. Ammonium sulfate was then added to the supernatant fluid to give a final concentration of 33%o, and the mixture allowed to stand for three hours at 40 C. The supernate was decanted after centrifugation and the precipitate redissolved in barbital buffer. This solution was dialyzed for four hours against running tap water and then for 16 hours against frequent changes of barbital buffer.
The effect of protamine sulfate on the anticoagulant activity of the patient's plasma was tested. A solution of protamine sulfate 2 was serially diluted with buffer. One-tenth ml. of the protamine solution was mixed with 0.1 ml. of the patient's native plasma in glass tubes. One ml. portions of fresh normal blood were added and the clotting times determined in duplicate at 370 C. Final concentrations of protamine tested were 80, 16, 8, 0.8, and 0.4 micrograms per ml.
Precipitin tests were performed in capillary tubes. The patient's oxalated native plasma was serially diluted with buffer and tested with normal oxalated plasma and with normal serum. The plasmas were oxalated by the addition of one part of 0.1 M sodium oxalate to nine parts of plasma. The capillary tubes were allowed to stand at room temperature for 24 hours and were observed for the presence of precipitate at frequent intervals during that time.
Thromboplastin was prepared from rabbit brain and from human brain by techniques previously described (14) .
A suspension of macerated platelets was prepared from hemophilic blood in the following manner. Blood was obtained without anticoagulant from a fasting hemophiliac and centrifuged at low speed for five minutes in siliconetreated test tubes. The supernatant plasma was removed and found to contain 428,000 platelets per cmm. Eighteen ml. of this plasma were then recentrifuged at 10,500 RPM in a Servall Superspeed angle centrifuge for 10 minutes. The sediment, which consisted of platelets, was washed with buffer and recentrifuged. It was then macerated with a glass mortar and pestle and resuspended in 3.5 ml. of buffer.
The crushed glass used in these experiments was prepared from Pyrex test tubes of the same lot used for the determination of clotting times. Particles which passed through a 50 mesh screen but which were retained by a 100 mesh screen were employed.
The clotting time of recalcified oxalated plasma was determined in glass tubes at 37°C. Blood was oxalated by the addition of one part of 0.1 M sodium oxalate to nine parts of whole blood and the plasma separated by centrifugation. One-half ml. of this plasma was recalcified with 0.1 ml. of 0.1 M calcium chloride in the presence of 0.1 ml. of the solution being tested. RESULTS 1. Inhibition of coagulation of normal blood by the patient's plasma The presence of anticoagulant activity in the patient's plasma was demonstrated by its inhibitory effect on the clotting of normal blood, as shown in Table I . As little as one part of the patient's plasma in 200 parts of normal blood prolonged significantly the clotting time of the latter.
Anticoagulant actizity of plasma protein fractions
There was no appreciable loss of clot inhibitory activity when the patient's plasma was dialyzed at low temperature for 24 hours against frequent 
Properties of the annticoagulant
The anticoagulant activity present in the patient's plasma persisted after the plasma was heated at 560 C. for 30 minutes. Heating the globulin fraction with the greatest anticoagulant activity to 560 C. for 30 minutes did not alter its activity, but there was some loss at 650 C. for 30 minutes. After heating at 800 C. for 10 minutes, the globulin fraction was inert in all concentrations tested. The patient's native platelet-deficient plasma was stored at about 50 C. for three months in silicone-treated test tubes without the addition of chemical anticoagulant. At the end of that time this plasma was still fluid. The stored plasma retained its anticoagulant activity, one part of plasma significantly prolonging the clotting time of 100 parts of fresh normal blood. Plasma similarly stored at 370 C. for 24 hours showed no loss of anticoagulant activity. However, when the patient's plasma was oxalated prior to storage at 50 C., there was a marked loss of anticoagulant activity after three months.
The effect of protamine sulfate on the anticoagulant activity of the patient's plasma was tested. The preparation of protamine employed had been demonstrated to overcome the clot-retarding action of heparin. However, in concentrations ranging from 0.4 to 80 micrograms per ml., it was ineffective in altering significantly the anticoagulant property of the patient's plasma. This observation indicates that the anticoagulant present in the patient's plasma did not resemble heparin.
The circulating anticoagulant occasionally encountered in hemophilic patients has been said to be an antibody (16 (Table III) . Therefore, it appeared that the anticoagulant did not inhibit the activity of thrombin. The clot accelerating effect of thromboplastin derived from rabbit brain was tested. This thromboplastin shortened the clotting time of recalcified oxalated plasma to the same degree in this patient inhibit the clot accelerating effect of the platelet suspension (Table VI) .
Finally, experiments were performed to determine whether a plasma thromboplastic factor was inhibited by the anticoagulant. Previous studies have shown that normal plasma clots on contact with glass surfaces in the virtual absence of platelets (7) . The rate of clotting of such plasma was found to be related to the surface area of the glass in contact with the plasma (8). However, platelet-deficient plasma from the patient under study failed to clot in glass tubes even when crushed glass was added. Furthermore, the addition of small amounts of the patient's plasma to normal platelet-deficient plasma retarded the clotting of the latter (Table VII) .
When the patient's plasma was diluted with buffer in glass tubes, coagulation did not occur in any dilution tested. The addition of crushed glass to the undiluted plasma likewise failed to induce coagulation. However, when crushed glass was added to appropriately diluted plasma, coagulation did occur (Table VIII) . This observation suggests that the patient's plasma contained po- tential thromboplastic activity. In undiluted plasma the circulating anticoagulant apparently inhibited the appearance of effective thromboplastic activity even upon the addition of crushed glass. However, when the plasma was diluted so that the concentration of anticoagulant was diminished, thromboplastic activity did appear when crushed glass was added.
It is an old observation that recalcified oxalated plasma clots more rapidly than unoxalated blood. The mechanism of this acceleration is not known. The effect of the patient's circulating anticoagulant on the recalcified plasma clotting time was tested (Table IX) . The coagulation of recalcified oxalated normal plasma was inhibited by small amounts of the patient's plasma. When crushed glass was added, this effect largely disappeared. Thus, in oxalated plasma as in native plasma the addition of crushed glass overcame the inhibitory effect of the diluted anticoagulant.
DISCUSSION
Previous studies have suggested the presence in plasma of a soluble factor necessary for the appearance of normal thromboplastic activity. The impaired coagulation in hemophilia is apparently related to deficient activity of such a factor. In hemophilia, the blood is known to contain normal amounts of prothrombin, accelerator globulin, fibrinogen, and platelets. The coagulation defect in this disease can be overcome by a substance present in normal plasma (11) . Hemophilic blood is known to clot normally in the presence of various thromboplastic agents. Therefore, it appears likely that the defective coagulation in hemophilia is attributable to deficient thromboplastic activity.
The mode of action of the plasma factor deficient in hemophilia is not yet clearly defined. The data from recent experimental studies provide convincing evidence that for normal clotting both a plasma factor and platelets are necessary (7, 17, 18) . Brinkhous (18) has suggested that the plasma factor serves to lyse platelets, which in turn release thromboplastin. Quick (17) , on the other hand, is of the opinion that the plasma factor is a "thromboplastinogen" which is converted to active thromboplastin by an enzyme released from disintegrating platelets.
The respective r6les of the platelets and of the plasma factor have been evaluated by studies of normal plasma from which the platelets have been remoyed (8) . These experiments indicated that essentially platelet-free plasma regularly clotted when in contact with glass surfaces, although it was often incoagulable when kept in siliconetreated vessels. The rate of clotting of such platelet-deficient plasma was a function of the surface area of the glass to which it was exposed. These studies have been interpreted to suggest that the plasma factor was present in circulating blood in an inactive state, and could be activated in some unknown manner upon contact with glass surfaces. The presence of platelets was not necessary for this activation, although the addition of platelets tremendously accelerated the formation of thrombin.
Further evidence in support of the existence of a potentially thromboplastic plasma factor has been provided by the study of certain patients whose plasma contained a circulating anticoagulant (12, 16, (19) (20) (21) (22) (23) (24) (25) (26) . Such an anticoagulant, present in the plasma of the patient described in this report, did not inhibit the action of thrombin, prothrombin, accelerator globulin, or a variety of thromboplastic substances including human and rabbit brain, platelet suspensions and Russell viper venom. Nevertheless, this anticoagulant was effective in retarding the coagulation of normal blood. The action of the anticoagulant, then, must have been exerted at an early stage of the clotting process. The data suggest that the anticoagulant prevented the appearance of thromboplastic activity in shed blood.
In previous studies it has been shown that essentially platelet-free human plasma clots when placed in glass tubes (7, 8) . Platelets thus appear not to be necessary for the initiation of clotting. The present study provides further support of this belief. The anticoagulant under study inhibited the coagulation of normal platelet-deficient plasma, although it had no demonstrable inhibitory effect against thromboplastin derived from platelets.
The anticoagulant described was precipitated with a globulin fraction of plasma. It was nondialyzable, and was destroyed by heating at 80°C. for 10 minutes. These properties suggest that the anticoagulant activity was associated with a protein. Precipitin studies did not provide any evidence that the clotting inhibitor was an antibody against a component of normal plasma.
SUMMARY
Evidence is presented which substantiates the view that platelet-free plasma contains a factor which is potentially thromboplastic. An anticoagulant is described which was present in the plasma of a patient with an atypical hemorrhagic diathesis. This anticoagulant retarded the clotting of normal blood. It did not inhibit the action of thrombin, prothrombin, accelerator globulin, platelets, or thromboplastin derived from various sources. The clot-inhibiting effect seems best explained by assuming that the anticoagulant inhibits the action of the plasma thromboplastic factor. BIBLIOGRAPHY
